WO2010127152A3 - Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors - Google Patents
Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors Download PDFInfo
- Publication number
- WO2010127152A3 WO2010127152A3 PCT/US2010/033022 US2010033022W WO2010127152A3 WO 2010127152 A3 WO2010127152 A3 WO 2010127152A3 US 2010033022 W US2010033022 W US 2010033022W WO 2010127152 A3 WO2010127152 A3 WO 2010127152A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- inhibitors
- compositions
- synthase
- microsomal prostaglandin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Provided herein are compounds, and pharmaceutical compositions comprising such compounds, wherein the compounds are inhibitors of mPGES-1 activity. Also provided herein are methods of using such compounds and composition to treat or prevent diseases or disorders associated with the activity of mPGES-1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17379509P | 2009-04-29 | 2009-04-29 | |
US61/173,795 | 2009-04-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010127152A2 WO2010127152A2 (en) | 2010-11-04 |
WO2010127152A3 true WO2010127152A3 (en) | 2011-09-29 |
Family
ID=42272690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/033022 WO2010127152A2 (en) | 2009-04-29 | 2010-04-29 | Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010127152A2 (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
EP2330894B8 (en) | 2008-09-03 | 2017-04-19 | BioMarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
CA2785204C (en) * | 2010-01-07 | 2016-01-05 | Selexagen Therapeutics, Inc. | Hedgehog inhibitors |
WO2011123609A1 (en) * | 2010-03-31 | 2011-10-06 | Glaxo Group Limited | Imidazolyl-imidazoles as kinase inhibitors |
AR084174A1 (en) | 2010-12-21 | 2013-04-24 | Lilly Co Eli | IMIDAZOL-2-BENZAMIDA COMPOUNDS USEFUL FOR THE TREATMENT OF OSTEOARTRITIS AND A PHARMACEUTICAL COMPOSITION |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
AU2012223509B2 (en) | 2011-02-28 | 2016-11-10 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
AR086254A1 (en) | 2011-05-26 | 2013-11-27 | Lilly Co Eli | USEFUL IMIDAZOL DERIVATIVES FOR THE TREATMENT OF ARTHRITIS |
JP2015503505A (en) * | 2011-12-23 | 2015-02-02 | ミレニアム ファーマシューティカルズ, インコーポレイテッドMillennium Pharmaceuticals, Inc. | Heteroaryl and uses thereof |
US9056874B2 (en) | 2012-05-04 | 2015-06-16 | Novartis Ag | Complement pathway modulators and uses thereof |
WO2013170770A1 (en) * | 2012-05-16 | 2013-11-21 | 上海医药集团股份有限公司 | Acetylene derivatives having antitumor activity |
WO2013186089A2 (en) | 2012-06-14 | 2013-12-19 | Basf Se | Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests |
US9475806B2 (en) | 2013-03-14 | 2016-10-25 | Novartis Ag | Complement factor B inhibitors and uses there of |
ES2680224T3 (en) | 2013-03-15 | 2018-09-05 | Biomarin Pharmaceutical Inc. | HDAC inhibitors |
EP3089963A1 (en) | 2013-10-30 | 2016-11-09 | Novartis AG | 2-benzyl-benzimidazole complement factor b inhibitors and uses thereof |
CA2935280A1 (en) * | 2014-01-21 | 2015-07-30 | F. Hoffmann-La Roche Ag | Imidazoles for the treatment and prophylaxis of respiratory syncytial virus infection |
ES2963906T3 (en) | 2017-11-22 | 2024-04-03 | Khondrion Ip B V | Compounds as MPGES-1 inhibitors |
WO2024041555A1 (en) * | 2022-08-24 | 2024-02-29 | Insilico Medicine Ip Limited | Methods of manufacturing kinase inhibitors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005123673A1 (en) * | 2004-06-18 | 2005-12-29 | Biolipox Ab | Indoles useful in the treatment of inflammation |
US20070208017A1 (en) * | 2004-12-17 | 2007-09-06 | Anh Chau | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
WO2008084218A1 (en) * | 2007-01-12 | 2008-07-17 | Boehringer Ingelheim International Gmbh | Benzazole derivatives for the treatment of inflammations |
WO2008139161A1 (en) * | 2007-05-10 | 2008-11-20 | Sareum Limited | Oxazole tyrosine kinase inhibitors |
-
2010
- 2010-04-29 WO PCT/US2010/033022 patent/WO2010127152A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005123673A1 (en) * | 2004-06-18 | 2005-12-29 | Biolipox Ab | Indoles useful in the treatment of inflammation |
US20070208017A1 (en) * | 2004-12-17 | 2007-09-06 | Anh Chau | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors |
WO2008084218A1 (en) * | 2007-01-12 | 2008-07-17 | Boehringer Ingelheim International Gmbh | Benzazole derivatives for the treatment of inflammations |
WO2008139161A1 (en) * | 2007-05-10 | 2008-11-20 | Sareum Limited | Oxazole tyrosine kinase inhibitors |
Non-Patent Citations (2)
Title |
---|
ST. LAURANT DR ET AL: "Preparation of 5-substituted 2-(2-alkyl/aryl-1H-imidazol-4-yl)oxazoles and 5-substituted 2-(2-alkyl/arylthiazol-4-yl)oxazoles by utilizing 5-substituted 2-(2-bromo-1,1-diethoxyethyl)oxazole as a synthon", SYNTHESIS, no. 9, 25 March 2009 (2009-03-25), pages 1445 - 1458, XP002589898 * |
TANAKA ET AL: "Studies on antiplatelet agents i. Synthesis and platelet inhibitory activity of 5-alkyl-2-aryl-4-pyridylimidazoles", CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 40, no. 12, 1 January 1992 (1992-01-01), pages 3206 - 3213, XP002651273 * |
Also Published As
Publication number | Publication date |
---|---|
WO2010127152A2 (en) | 2010-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010127152A3 (en) | Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
PL2134704T3 (en) | Compounds and compositions as modulators of gpr119 activity | |
MX2009007944A (en) | Compounds and compositions as kinase inhibitors. | |
WO2011014795A3 (en) | Compounds and compositions as syk kinase inhibitors | |
WO2009089494A3 (en) | Pharmaceutical compositions | |
WO2008118332A3 (en) | Hydrazido-peptides as inhibitors of hcv ns3-protease | |
MX2012004078A (en) | Compounds and compositions as modulators of gpr119 activity. | |
WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
EA200901032A1 (en) | COMPOUNDS AND COMPOSITIONS AS GPR119 ACTIVITY MODULATORS | |
WO2010083207A3 (en) | Protein kinase c inhibitors and uses thereof | |
EA201100138A1 (en) | 4-PHENOXYMETHYL-PIPERIDINES AS MODEL ACTIVITY GPR119 | |
TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
EA026892B9 (en) | TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS | |
WO2010127099A3 (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
WO2009129246A3 (en) | Compositions and methods for preparing and using same | |
WO2008033562A3 (en) | Kinase inhibitor compounds | |
WO2012125544A3 (en) | Necroptosis inhibitors and methods of use therefor | |
UA103930C2 (en) | Normal;heading 1;heading 2;heading 3;COMPOUNDS AND COMPOSITION FOR THE TREATMENT OF PARASITIC DISEASES | |
MY144970A (en) | Heterocyclic compounds | |
WO2008070268A3 (en) | Pharmaceutical compositions | |
IN2012DN03182A (en) | ||
WO2007125105A3 (en) | Benzamide glucokinase activators | |
WO2010147830A3 (en) | Aminothiazole modulators of beta-3-adrenoreceptor | |
WO2011088160A3 (en) | Novel cyp17 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10717391 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10717391 Country of ref document: EP Kind code of ref document: A2 |